PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential

References

• Jiang TM, Ma Y, Mao W, Mao Q, You Y, Yang X, Jiang C, Kang C, Li X, Chen L, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2016;375(2):263–73. doi:10.1016/j.canlet.2016.01.024.
   PubMed Web of Science ®Google Scholar
• Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RGW, Zhou S, Fuller GN, Khasraw M, de Groot J, et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016;18(10):1357–66. doi:10.1093/neuonc/now132.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. doi:10.1056/NEJMoa1503093.
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, Arance A, Grob -J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–62. doi:10.1016/S0140-6736(17)31601-X.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob -J-J, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-CELL LUNG CANCER. N Engl J Med. 2018;379(23):2220–29. doi:10.1056/NEJMoa1809064.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Piha-Paul SA, et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318-327. doi: 10.1200/JCO.2018.78.2276
   PubMed Web of Science ®Google Scholar
• Reiss SN, Yerram P, Modelevsky L, Grommes C. Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas. J Immunother Cancer. 2017;5(1):99. doi:10.1186/s40425-017-0302-x.
   PubMed Web of Science ®Google Scholar
• Kurz SC, Cabrera LP, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee EQ, Reardon DA, Wen PY, et al. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018;91(14):e1355–e1359. doi:10.1212/WNL.0000000000006283.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Brandes AA, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, de Souza P, Ahluwalia MS, Lim M, et al. Randomized phase 3 study evaluating the efficacy and safety of nivolumab Vs bevacizumab in patients with recurrent glioblastoma: checkmate 143. neuro-oncology. 2017;19(suppl_3):iii21. doi:10.1093/neuonc/nox036.071.
   Google Scholar
• Chen RQ, Liu F, Qiu XY, Chen XQ. The prognostic and therapeutic value of PD-L1 in glioma. Front Pharmacol. 2018;9:1503. doi:10.3389/fphar.2018.01503.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29. doi:10.1056/NEJMoa1709937.
   PubMed Web of Science ®Google Scholar
• Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, Fassò M, Osborne S, Molinero L, O’Hear C, et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018;140(2):317–28. doi:10.1007/s11060-018-2955-9.
   PubMed Web of Science ®Google Scholar
• Caccese M, Indraccolo S, Zagonel V, Lombardi G. PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review. Crit Rev Oncol Hematol. 2019;135:128–34. doi:10.1016/j.critrevonc.2018.12.002.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Kaley TJ, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy TF, Gan HK, Park AJ, Schwarzenberger P, et al. Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab DUR]) in glioblastoma (GBM) patients: an update. JCO. 2017;35(15):2042–2042. doi:10.1200/JCO.2017.35.15_suppl.2042.
   Web of Science ®Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17(8):1064–75. doi:10.1093/neuonc/nou307.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218. doi:10.1038/s41573-018-0007-y.
   PubMed Web of Science ®Google Scholar
• Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017;19(6):796–807. doi:10.1093/neuonc/now287.
   PubMed Web of Science ®Google Scholar
• Maxwell R, Jackson CM, Lim M. Clinical trials investigating immune checkpoint blockade in glioblastoma. Curr Treat Options Oncol. 2017;18(8):51. doi:10.1007/s11864-017-0492-y.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Wei J, Yaghi NK, Huang N, Kong L-Y, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18(2):195–205. doi:10.1093/neuonc/nov172.
   PubMed Web of Science ®Google Scholar
• Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 2016;6(11):1230–36. doi:10.1158/2159-8290.CD-16-0575.
   PubMed Web of Science ®Google Scholar
• Barresi V, Simbolo M, Mafficini A, et al. Ultra-mutation in IDH wild-type glioblastomas of patients younger than 55 years is associated with defective mismatch repair, microsatellite instability, and giant cell enrichment. Cancers (Basel). 2019;11(9):1279. doi:10.3390/cancers11091279.
   PubMed Web of Science ®Google Scholar
• Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7(5):335–46. doi:10.1038/nrm1907.
   PubMed Web of Science ®Google Scholar
• Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016;34(19):2206–11. doi:10.1200/JCO.2016.66.6552.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44. doi:10.1016/j.cell.2016.02.065.
   PubMed Web of Science ®Google Scholar
• Costantini A, Takam Kamga P, Dumenil C, Chinet T, Emile J-F, Giroux Leprieur E. Plasma biomarkers and immune checkpoint inhibitors in non-small cell lung cancer: new tools for better patient selection? Cancers (Basel). 2019;11(9):1269. doi:10.3390/cancers11091269.
   PubMed Web of Science ®Google Scholar
• Dawood S. The evolving role of immune oncology in colorectal cancer. Chin Clin Oncol. 2018;7(2):17–17. doi:10.21037/cco.2018.04.07.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–e551. doi:10.1016/S1470-2045(16)30406-5.
   PubMed Web of Science ®Google Scholar
• Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171(5):1042–1056 e10.
   PubMed Web of Science ®Google Scholar
• Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther. 2018;189:45–62. doi:10.1016/j.pharmthera.2018.04.004.
   PubMed Web of Science ®Google Scholar
• Tiffany R, Hodges MO, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro-Oncology. 2017;19:047–1057.
   Web of Science ®Google Scholar
• Adrienne Johnson ES, Gay L, Vergilio J-A, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Ali S, Miller V, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumormutational burden, and hypermutation signatures. Oncologist. 2017;22:1478–90. doi:10.1634/theoncologist.2017-0242.
   PubMed Web of Science ®Google Scholar
• Giuseppe Lombardi MC, Simonelli M, Fassan M, Padovan M, Persico P, Bellu L, Dipasquale A, PaolaGardiman M, Indraccolo S, Zagonel V. Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients (PTS) with mismatch repair deficiency (MMRd): an observational study. Am Soc Clin Oncol. 2019;2043. doi:10.1200/JCO.2019.37.15_suppl.2043.
   Web of Science ®Google Scholar
• Berghoff ASPM. Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome? Nat Rev Neurol. 2019;15(6):314–15. doi:10.1038/s41582-019-0178-0.
   PubMed Web of Science ®Google Scholar
• Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-diaz de Cerio A, Tejada S, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019;25(3):470–76. doi:10.1038/s41591-018-0339-5.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–86. doi:10.1038/s41591-018-0337-7.
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462–69. doi:10.1038/s41591-019-0349-y.
   PubMed Web of Science ®Google Scholar
• Dai B, Qi N, Li J, Zhang G. Temozolomide combined with PD-1 antibody therapy for mouse orthotopic glioma model. Biochem Biophys Res Commun. 2018;501(4):871–76. doi:10.1016/j.bbrc.2018.05.064.
   PubMed Web of Science ®Google Scholar
• Park J, Kim CG, Shim J-K, Kim JH, Lee H, Lee JE, Kim MH, Haam K, Jung I, Park S-H, et al. Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma. Oncoimmunology. 2019;8(1):e1525243. doi:10.1080/2162402X.2018.1525243.
   PubMed Web of Science ®Google Scholar
• Silu Wang FY, Lu X, Li Q, Su Z, Lee J-H, Wang C, Linyong D. Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma. EMBO Mol Med. 2019;11:e8492.
   PubMed Web of Science ®Google Scholar
• Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 2018;20(12):1566–72. doi:10.1093/neuonc/noy072.
   PubMed Web of Science ®Google Scholar
• Heynckes S, Daka K, Franco P, Gaebelein A, Frenking JH, Doria-Medina R, Mader I, Delev D, Schnell O, Heiland DH, et al. Crosslink between temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme. BMC Cancer. 2019;19(1):117. doi:10.1186/s12885-019-5308-y.
   PubMedGoogle Scholar
• Mathios D, Kim JE, Mangraviti A, Phallen J, Park C-K, Jackson CM, Garzon-Muvdi T, Kim E, Theodros D, Polanczyk M, et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med. 2016;8(370):370ra180. doi:10.1126/scitranslmed.aag2942.
   PubMed Web of Science ®Google Scholar
• Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343–49. doi:10.1016/j.ijrobp.2012.12.025.
   PubMed Web of Science ®Google Scholar
• Field KM, Jordan JT, Wen PY, Rosenthal MA, Reardon DA. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. 2015;121(7):997–1007. doi:10.1002/cncr.28935.
   PubMed Web of Science ®Google Scholar
• Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. The role of bevacizumab in the treatment of glioblastoma. J Neurooncol. 2017;133(3):455–67. doi:10.1007/s11060-017-2477-x.
   PubMed Web of Science ®Google Scholar
• Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385):eaak9679. doi:10.1126/scitranslmed.aak9679.
   PubMed Web of Science ®Google Scholar
• Tamura R, Tanaka T, Ohara K, Miyake K, Morimoto Y, Yamamoto Y, Kanai R, Akasaki Y, Murayama Y, Tamiya T, et al. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. Cancer Sci. 2019;110(2):499–508. doi:10.1111/cas.13889.
   PubMed Web of Science ®Google Scholar
• Joller N, Kuchroo VK. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol. 2017;410:127–56. doi:10.1007/82_2017_62.
   PubMed Web of Science ®Google Scholar
• Hung AL, Garzon-Muvdi T, Lim M. Biomarkers and immunotherapeutic targets in glioblastoma. World Neurosurg. 2017;102:494–506. doi:10.1016/j.wneu.2017.03.011.
   PubMed Web of Science ®Google Scholar
• Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H, et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res. 2017;23(1):124–36. doi:10.1158/1078-0432.CCR-15-1535.
   PubMed Web of Science ®Google Scholar
• Harris-Bookman S, Mathios D, Martin AM, Xia Y, Kim E, Xu H, Belcaid Z, Polanczyk M, Barberi T, Theodros D, et al. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. Int J Cancer. 2018;143(12):3201–08. doi:10.1002/ijc.31661.
   PubMed Web of Science ®Google Scholar
• Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyanage H, Schroeder M, Sarkaria J, Johnson AJ, Galanis E, et al. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol. 2017;19(4):493–502. doi:10.1093/neuonc/now179.
   PubMed Web of Science ®Google Scholar
• Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016;1(10). doi:10.1172/jci.insight.87059.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35. doi:10.1016/j.immuni.2019.12.011.
   PubMed Web of Science ®Google Scholar
• Squibb B-M, Bristol-myers squibb announces phase 3 CheckMate 498 study did not meet primary endpoint of overall survival with opdivo (nivolumab) plus radiation in patients with newly diagnosed MGMT-unmethylated glioblastoma multiforme. 2019 May 9. Accessed 2019 Nov 15. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-498-study-did
   Google Scholar
• Squibb B-M Bristol-myers squibb provides update on phase 3 opdivo (nivolumab) CheckMate −548 trial in patients with newly diagnosed MGMT-methylated glioblastoma multiforme. 2019 Sep 5. Accessed 2018 Nov 9. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-provides-update-phase-3-opdivo-nivolumab-]
   Google Scholar
• A, Reardon TJK, Dietrich J, Clarke JL, Dunn G, Lim M, Cloughesy TF, Gan HK, Park AJ, Schwarzenberger P, et al. Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). J Clin Oncol 37, 2019 (suppl; abstr 2032) DOI: 10.1200/JCO.2019.37.15_suppl.2032
   Google Scholar
• Reardon DANL, Peters KB, Peters KB, Clarke JL, Jordan JT, De Groot JF, Nghiemphu PL, Kaley TJ, Colman H, Gaffey SC, et al. Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. J Clin Oncol. 2018;36:2006. doi:10.1200/JCO.2018.36.15_suppl.2006.
   PubMed Web of Science ®Google Scholar
• Reardon DAGJ, Colman H, Jordan JT, Daras M, Clarke JL, Nghiemphu PL, Gaffey SC, Peters KB. Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). J Clin Oncol. 2016;34. doi:10.1200/JCO.2016.34.15_suppl.2010.
   Web of Science ®Google Scholar
• Sahebjam SJP, Forsyth PAJ, Arrington J, Vrionis FD, Etame AB, Tran ND, Dalvi PH, Kim S, Macaulay RJ, Chinnaiyan P, et al. Safety and antitumor activity of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab (Pembro) and bevacizumab (Bev) in patients (pts) with recurrent high grade gliomas: preliminary results from phase I study. J Clin Oncol. 2016;34. doi:10.1200/JCO.2016.34.15_suppl.2041.
   Web of Science ®Google Scholar
• David Reardon TK, Dietrich J, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy T, Gan HK, Park A, Schwarzenberger P, et al. Atim-12. Phase 2 study to evaluate the clinical efficacy and safety of Medi4736 (Durvalumab [DUR]) in patients with Bevacizumab (BEV)-refractory recurrent Glioblastoma (GBM). neuro-oncology. 2017;19(suppl_6):vi28. doi:10.1093/neuonc/nox168.108.
   Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar
• Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018;20(5):674–86. doi:10.1093/neuonc/nox208.
   PubMed Web of Science ®Google Scholar
• Cousin S, Seneschal J, Italiano A. Toxicity profiles of immunotherapy. Pharmacol Ther. 2018;181:91–100. doi:10.1016/j.pharmthera.2017.07.005.
   PubMed Web of Science ®Google Scholar
• Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH. The safety of available immunotherapy for the treatment of glioblastoma. Expert Opin Drug Saf. 2017;16(3):277–87. doi:10.1080/14740338.2017.1273898.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, et al. Management of immunotherapy-related toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019;17(3):255–89. doi:10.6004/jnccn.2019.0013.
   PubMed Web of Science ®Google Scholar
• Thompson JA. New NCCN guidelines: recognition and management of immunotherapy-related toxicity. J Natl Compr Canc Netw. 2018;16(5S):594–96. doi:10.6004/jnccn.2018.0047.
   PubMed Web of Science ®Google Scholar
• Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–iv142. doi:10.1093/annonc/mdx225.
   PubMed Web of Science ®Google Scholar
• Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1–8. doi:10.1016/j.ejca.2016.12.001.
   PubMed Web of Science ®Google Scholar
• Lim MOA, Vlahovic G, Reardon DA, Sahebjam S, Cloughesy T, Cloughesy T, Baehring J, Butowski N, Potter V, Zwirtes R, et al. Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM). Ann Oncol. 2017;28:v109–21. doi:10.1093/annonc/mdx366.
   Web of Science ®Google Scholar
• Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017;19(5):625–35. doi:10.1093/neuonc/nox029.
   PubMed Web of Science ®Google Scholar
• Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–e542. doi:10.1016/S1470-2045(15)00088-1.
   PubMedGoogle Scholar
• Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95. doi:10.1186/s40425-017-0300-z.
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, Kähler KC, Loquai C, Reinmuth N, Steins M, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18. doi:10.1016/j.ctrv.2016.02.003.
   PubMed Web of Science ®Google Scholar
• Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395–e403. doi:10.1016/S1470-2045(14)70011-7.
   PubMed Web of Science ®Google Scholar
• Kelly WJ, Gilbert MR. Glucocorticoids and immune checkpoint inhibitors in glioblastoma. J Neurooncol. 2020. doi:10.1007/s11060-020-03439-2.
   PubMed Web of Science ®Google Scholar
• Williams KJ, Grauer DW, Henry DW, Rockey ML. Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors. J Oncol Pharm Pract. 2019;25(3):544–50. doi:10.1177/1078155217744872.
   PubMed Web of Science ®Google Scholar
• Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1):51. doi:10.1186/s40425-018-0371-5.
   PubMed Web of Science ®Google Scholar
• Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139(Pt 5):1458–71. doi:10.1093/brain/aww046.
   PubMed Web of Science ®Google Scholar